See the DrugPatentWatch profile for cosentyx

Based on the information provided, there is no direct link established between Cosentyx and higher injection site reactions to vaccines. Cosentyx, also known as secukinumab, is a medication used to treat various conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1].

The drug works by targeting a specific protein in the body's immune system called interleukin-17A (IL-17A), which is involved in inflammatory processes [1]. There is no mention of Cosentyx increasing the risk of injection site reactions to vaccines in the drug's prescribing information or clinical trial data [1][2].

However, it is important to note that any injection at the same site as Cosentyx could potentially lead to an injection site reaction. The Cosentyx prescribing information advises healthcare providers to rotate injection sites with each administration to minimize the risk of injection site reactions [2].

In conclusion, while there is no direct link between Cosentyx and higher injection site reactions to vaccines, it is always important to follow the prescribing information and rotate injection sites when administering Cosentyx.

Sources:
[1] DrugPatentWatch.com. Cosentyx (secukinumab) Drug Profile. <https://www.drugpatentwatch.com/drugs/cosentyx>.
[2] Novartis Pharmaceuticals Corporation. Cosentyx (secukinumab) [prescribing information]. January 2022. <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>.